

### DETAILED ACTION

1. This application is a RCE of SN 10/522,207 filed July 14, 2010.  
Two IDS submitted July 14, 2010 have been initialed and attached.  
Claims 12, 15-30 have been canceled. Claims 1-11, 13-14 are pending.

2. **Reason for Allowance**

The following is an examiner's statement of reasons for allowance:

Applicants have deleted the scope of prodrug thus obviated the 112 first and second paragraph rejections. Applicants have explicitly included the "S" or "R" notation at each chiral center thus obviated the ambiguity and anticipation, thus, the rejection under 35 USC 102(b). Applicants argued that although azasugars are known for biological activity but modification in stereo-relationships have been evidenced to be highly unpredictable of maintaining the same activity as the parent compound such as pointed out by applicant that:

*"as can be seen (in hindsight) in Tables 2 and 3 of Kato et al., L-ido-DNJ and L-manno-DNJ are not active against any enzyme at all and would not be an alternative choice for D-manno-DNJ or D-ido-DNJ as one isomer has inhibitory activities against specific glycosidases while the other isomer does or may not have inhibitory activities at all. Therefore, it is difficult to rationalize, in hindsight, the inhibitory activities of the various enantiomers of imino sugar compounds, let alone predict the activity of an enantiomer against a particular enzyme"* (p.12 response 8/3/09)

Therefore, the currently amended claims explicitly pointed to the very particular enantiomer of formula I are neither anticipated nor rendered obvious by the art of record. The rejections under 35 USC 103(a) or obviousness type double patenting are dropped. Claims 1-11, 13-14 are allowed.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

3. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Celia Chang, Ph. D. whose telephone number is 571-272-0679. The examiner can normally be reached on Monday through Thursday from 8:30 am to 5:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Janet L. Andres, Ph. D., can be reached on 571-272-0867. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

OACS/Chang  
Feb. 24, 2011

/Celia Chang/  
Primary Examiner  
Art Unit 1625